Ligand to Report First Quarter 2025 Financial Results on May 8, 2025
Ligand Pharmaceuticals (Nasdaq: LGND) has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results and provide a business update.
The conference call will be accessible via phone at (800) 715-9871 for U.S. & Canada callers and (646) 307-1963 for international participants, using Conference ID 3661098. A live webcast and replay of the call will also be available.
Ligand Pharmaceuticals (Nasdaq: LGND) ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per giovedì 8 maggio 2025, prima dell'apertura dei mercati statunitensi. La società terrà una conference call e una diretta web alle 8:30 a.m. ET dello stesso giorno per discutere i risultati e fornire un aggiornamento sull'attività.
La conference call sarà accessibile telefonicamente al numero (800) 715-9871 per chiamate dagli Stati Uniti e Canada e al (646) 307-1963 per partecipanti internazionali, utilizzando il codice ID conferenza 3661098. Saranno disponibili anche la diretta web e la registrazione della chiamata.
Ligand Pharmaceuticals (Nasdaq: LGND) ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el jueves 8 de mayo de 2025, antes de la apertura de los mercados en EE.UU. La compañía realizará una conferencia telefónica y una transmisión en vivo a las 8:30 a.m. ET ese mismo día para discutir los resultados y ofrecer una actualización del negocio.
La conferencia telefónica será accesible por teléfono al (800) 715-9871 para llamadas desde EE.UU. y Canadá y al (646) 307-1963 para participantes internacionales, utilizando el ID de conferencia 3661098. También estará disponible la transmisión en vivo y la repetición de la llamada.
Ligand Pharmaceuticals (나스닥: LGND)는 2025년 1분기 재무 실적 발표를 2025년 5월 8일 목요일 미국 시장 개장 전에 진행할 예정입니다. 회사는 같은 날 동부 표준시 오전 8시 30분에 실적에 대해 논의하고 사업 현황을 업데이트하는 컨퍼런스 콜과 웹캐스트를 개최합니다.
컨퍼런스 콜은 미국 및 캐나다 발신자는 (800) 715-9871, 국제 참가자는 (646) 307-1963으로 전화 접속할 수 있으며, 회의 ID는 3661098입니다. 생중계 웹캐스트와 통화 녹음도 제공됩니다.
Ligand Pharmaceuticals (Nasdaq : LGND) a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le jeudi 8 mai 2025, avant l'ouverture des marchés américains. La société tiendra une conférence téléphonique et une diffusion en direct à 8h30 ET le même jour pour discuter des résultats et fournir une mise à jour commerciale.
La conférence téléphonique sera accessible par téléphone au (800) 715-9871 pour les appelants des États-Unis et du Canada, et au (646) 307-1963 pour les participants internationaux, en utilisant l'ID de conférence 3661098. Un webcast en direct et un replay de l'appel seront également disponibles.
Ligand Pharmaceuticals (Nasdaq: LGND) hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für Donnerstag, den 8. Mai 2025, vor Öffnung der US-Märkte, geplant. Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen und ein Geschäftsupdate zu geben.
Die Telefonkonferenz ist telefonisch unter (800) 715-9871 für Anrufer aus den USA und Kanada sowie unter (646) 307-1963 für internationale Teilnehmer erreichbar, mit der Konferenz-ID 3661098. Ein Live-Webcast und eine Aufzeichnung des Anrufs werden ebenfalls verfügbar sein.
- None.
- None.
JUPITER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, May 8, 2025. The company will hold a conference call that same day beginning at 8:30 a.m. ET to discuss the results and provide a general business update.
| Conference Call and Webcast Information | ||
| Date: | Thursday, May 8, 2025 | |
| Time: | 8:30 AM Eastern Time | |
| Conference Call: | (800) 715-9871 (U.S. & Canada) | |
| (646) 307-1963 (International) | ||
| Conference ID 3661098 | ||
| Webcast: | Live and replay webcasts of the call are available here. | |
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X and LinkedIn.
We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.
Contacts
Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761
Media:
Kellie Walsh
media@ligand.com
(914) 315-6072
FAQ
When will Ligand (LGND) release Q1 2025 earnings?
How can investors join Ligand's (LGND) Q1 2025 earnings call?
What time is Ligand's (LGND) Q1 2025 earnings conference call?
Will there be a replay available for Ligand's (LGND) Q1 2025 earnings call?
